Oral Delivery Breakthrough Opens Door to a Massive New Medical Market

2026-02-10 15:56:28 ET

Medical cannabis is entering a new phase of global adoption as regulators expand approved delivery methods beyond oils and inhalation. Across large emerging healthcare markets, physicians and patients are increasingly focused on formats that offer faster onset, precise dosing, and improved adherence, particularly for chronic conditions where consistency and discretion matter. Recent regulatory shifts in Latin America are accelerating this trend, opening the door for novel pharmaceutical-style cannabis products designed for mainstream medical use.

Shares of Rapid Dose Therapeutics Corp. ( CSE: DOSE ) ( OTCQB: RDTCF ) are in focus Tuesday following the company’s announcement that it has officially launched its QuickStrip™ medical cannabis product in Brazil after receiving regulatory approval from the country’s National Health Regulatory Agency, ANVISA. The approval covers both manufacturing and distribution and allows for sublingual and buccal administration, positioning the company among the first to bring an orally dissolvable strip cannabis therapy to the Brazilian medical market.

Rapid Dose Therapeutics is a Canadian biotechnology company focused on innovative drug delivery solutions. Its flagship QuickStrip™ technology is a rapidly dissolving oral thin film designed to deliver controlled doses of active ingredients through the oral mucosa, enabling faster absorption and more predictable effects compared to traditional oral formulations.

The Brazilian launch is being executed through a strategic partnership with Nexxions, the company’s U.S.-based distribution and commercialization partner, and Entourage Phytolab, a Brazilian pharmaceutical company specializing in cannabinoid-based medicines. Nexxions played a key role in navigating Brazil’s regulatory framework and securing market access in what remains a highly regulated environment.

Brazil represents one of the most attractive growth opportunities for medical cannabis globally. With a population exceeding 215 million, the country has reported more than 672,000 registered cannabis patients, a figure that rose 56 percent year over year. Recent regulatory changes in January 2026 expanded permitted routes of administration to include sublingual and buccal delivery, alongside dermatological and inhalation methods, significantly broadening treatment options for patients.

QuickStrip™ is designed to address several limitations associated with oils, capsules, and inhaled products. Oral mucosal absorption offers rapid onset, while the thin strip format allows for discreet, portable use. Precise dosing supports physician oversight and treatment consistency, and the non-inhalable format makes the product suitable for patients with respiratory concerns.

Executives at Entourage Phytolab cited early patient feedback showing rapid relief, often within minutes, and longer-than-expected duration of benefit. Company leadership highlighted the ease of use as a key differentiator in a market where many patients struggle with swallowing pills or tolerating the taste and variability of oils.

Rapid Dose Therapeutics’ management described the Brazilian launch as a meaningful milestone in its broader international growth strategy, noting that partnerships in Brazil and across South America position the company to address rising demand for pharmaceutical-grade cannabis therapies as regulations continue to evolve.

Shares of DOSE were up 10.3 percent at C$0.16 in Tuesday afternoon trading, while RDTCF shares were flat at $0.076.

Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View more of this article on AllPennyStocks.com.

About AllPennyStocks.com Media, Inc.:

Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.

Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.

AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.

Contact:

AllPennyStocks.com Media, Inc.

Email: ads@allpennystocks.com

Phone: (800) 558-4560 Ext: 101